ST未名 (002581)
Shandong Sinobioway Biomedicine Co., Ltd.
K-Line Chart
No K-line data available
Company NameShandong Weiming Biotechnology Pharmaceutical Co., Ltd.
Listing Date2011-05-20
Issue Price19RMB
Registered Capital65973.558610k RMB
Legal RepresentativeYue Jialin
Registered AddressNo. 28, South Branch 1 Road (Xingyuan Road), Zibo Science and Technology Industrial Park, Zhangdian District, Zibo City, Shandong Province
IndustryBiological Products
Main BusinessResearch, development, production, and sales of high-value-added pesticide and pharmaceutical intermediates such as trimethyl orthoformate and triethyl orthoformate.
Company ProfileShandong Weiming Biotechnology Pharmaceutical Co., Ltd. aims to establish a health product supply system by developing the biomedicine industry; to build a health service system with Chinese characteristics by developing modern traditional Chinese medicine; and to establish a life health management system by implementing the GHP plan. Weiming Pharmaceutical will focus on developing three major systems: drug manufacturing, new drug R&D, and product distribution, to build a comprehensive health product supply system. Through the implementation of the 'Hundreds, Thousands, Millions, Billions Project', the company aims to achieve the following goals by 2030: Weiming Pharmaceutical will account for 10% of the total sales in China's pharmaceutical market and 50% of the total sales in the biomedicine market, with the market capitalization of its listed company (002581) exceeding one trillion yuan; by establishing a new drug expressway, Weiming Pharmaceutical will obtain 25 new drug certificates annually; through international corporate restructuring and mergers and acquisitions, Weiming Pharmaceutical will become the world's largest pharmaceutical enterprise group.
Stock Details
1. Key Indicators
- Total Shares(W): 65973.56
- Circulating A-Shares(W): 40079.12
- Earnings Per Share(RMB): -0.1043
- Net Assets Per Share(RMB): 2.8335
- Operating Revenue(W RMB): 21205.00
- Total Profit(W RMB): -10259.34
- Net Profit Attributable to Parent(W RMB): -6881.07
- Net Profit Growth Rate(%): -570.46
- Weighted Return on Equity(%): -3.6200
- Operating Cash Flow Per Share(RMB): -0.3490
- Undistributed Profit Per Share(RMB): 0.9197
- Capital Reserve Per Share(RMB): 1.3353
2. Main Business
The main business covers:
- Interferon, nerve growth factor, vaccines and other biopharmaceutical sectors
3. Company Basic Information
- Company Name: Shandong Sinobioway Biomedicine Co., Ltd.
- Listing Date: 2011-05-20
- Industry: Pharmaceutical Manufacturing
- Address: 27F, Qimei Building, Intersection of Xinhuan East Road and Rong'er Road, Mashang Sub-district Office, Zhangdian District, Zibo City, Shandong Province
- Website: www.bioway-pku.com
- Company Profile: The issuer was approved by the Shandong Provincial Department of Commerce's document "Lu Shang Wai Zi Zi [2009] No. 289" dated October 26, 2009, "Approval on Agreeing to the Transformation of Zibo Wanchang Technology Development Co., Ltd. into a Foreign-invested Joint Stock Limited Company," and was established as a foreign-invested joint stock limited company through the overall change of Wanchang Development. According to the "Audit Report" issued by Daxin Certified Public Accountants, "Da Xin Shen Zi [2009] 3-0364," Wanchang Development converted its audited net assets of RMB 103,970,845.23 as of June 30, 2009, into the company's share capital of RMB 58 million, with the remaining RMB 45,970,845.23 credited to capital reserve. The shareholders subscribed for the company's shares with the net assets corresponding to their respective equity interests in Wanchang Development. Daxin Certified Public Accountants issued the "Capital Verification Report" "Da Xin Yan Zi [2009] 3-0018," confirming that the contributions of all promoters had been made. The issuer was registered with the Shandong Provincial Administration for Industry and Commerce on November 16, 2009, with a registered capital of RMB 58 million, and obtained the "Business License of Enterprise Legal Person" with registration number 370300400000903.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenwan Hongyuan Securities Co., Ltd. | Securities Company | 579.00 | 1.44 |
5. Concept Sectors
- ST Sector
- Biological Vaccine
- Gene Concept
- CXO Concept
- Hepatitis Concept
- Innovative Drug
- Securities Firm Heavy Holdings
- University Background
- Decreasing Shareholder Number
- Intended Reduction
- Below Issue Price
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information